Direkt zum Inhalt
Merck
  • Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.

Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.

Cancer genomics & proteomics (2016-04-24)
David J Birnbaum, François Bertucci, Pascal Finetti, José Adélaïde, Marc Giovannini, Olivier Turrini, Jean Robert Delpero, Jean Luc Raoul, Max Chaffanet, Vincent Moutardier, Daniel Birnbaum, Emilie Mamessier
ZUSAMMENFASSUNG

Individual molecular information might improve management of pancreatic adenocarcinoma. To identify actionable genes, at the transcriptional level, we investigated candidate genes that we had previously identified using array-comparative genomic hybridization (aCGH). We collected 10 public gene-expression datasets, gathering a total of 524 pancreatic samples (105 normal and 419 malignant tissues). Based on our previous aCGH analysis, we searched for genes differentially expressed between normal and malignant samples and genes associated with survival. Among genes amplified/gained by aCGH, 48% were overexpressed in malignant tissues. The majority of these genes were related to apoptosis, cell-cycle regulation and differentiation. Among genes located in areas of loss, 41% were underexpressed in malignant tissues; most of them were involved in ion transport, homeostasis maintenance and fatty acid metabolism. Survival analysis identified genes significantly related to shorter (n=17) or longer (n=29) survival. Some of these genes can be further investigated as potential prognostic markers.